Form 4: Sarepta Therapeutics Director Claude Nicaise Reports Stock Option Exercise and Sale
SEC Form 4
Director Claude Nicaise exercised stock options and sold shares of Sarepta Therapeutics on March 12, 2025.
Summary
- On March 12, 2025, Claude Nicaise, a director of Sarepta Therapeutics, exercised stock options to purchase 9,746 shares of common stock at a price of $25.18 per share.
- Following the exercise, Nicaise sold 2,491 shares of common stock at a weighted average price of $99.64, with prices ranging from $99.64 to $99.87.
- After these transactions, Nicaise directly owns 27,812 shares of Sarepta Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the trading activities of company directors. It's a standard practice for publicly traded companies and their executives.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider trading activity.
Key Dates
| Date | Description |
|---|---|
| 06/02/2016 | Date stock options were granted. |
| 06/02/2025 | Expiration date of the stock options. |
| 03/12/2025 | Date of the stock option exercise and share sale. |
| 03/13/2025 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.